Skip to main content

Read the latest news about research and scientific resultats on Alzheimer's disease at the Barcelonaβeta Brain Research Center (BBRC).

30 Nov | 2022

A new research drug against Alzheimer's confirms its positive results during CTAD

The results, published in The New England Journal of Medicine, confirm that lecanemab slows cognitive decline by 27% in patients in the early stages of Alzheimer's disease.

16 Nov | 2022

The validity of nine biomarkers for diagnosing Alzheimer's disease in daily clinical practice has been determined

A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre and the University of Gothenburg has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres.

03 Nov | 2022

New data indicate an association between poor sleep quality and an increased risk of developing Alzheimer's

The research, within the European project EPAD, is headed by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, together with the University of Bristol.

18 Oct | 2022

Relationship between symptoms of anxiety and depression during confinement and subjective cognitive decline found

In the research, led by the BBRC, 250 people without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation, have participated.

30 Aug | 2022

A new BBRC study links Alzheimer's biomarkers to symptoms of anxiety and depression during confinement by Covid-19

More than 900 people without cognitive alterations from the Alfa Study, which has the support of the "la Caixa" Foundation, have participated in the research.

11 Aug | 2022

A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's

The study, which used data from almost 400 participants of the ALFA+ Study, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms.

18 Jul | 2022

A new study shows that alterations in biomarkers are associated with higher volumes of gray matter and an increase in glucose metabolism in the brain in cognitively healthy people

Research helps to better understand the relationship between biomarkers of Alzheimer’s disease and the pathophysiological mechanisms that are altered in their early stages.

05 May | 2022

The researcher Marta Milà defends the third doctoral thesis done at the BBRC

The thesis develved into urrent knowledge of the disease during its preclinical stage and provides new evidence for its early detection.

19 Oct | 2021

Identified in the blood a biomarker that allows to detect in a very precise way the initial phases of the Alzheimer’s disease

Researchers at the Pasqual Maragall Foundation's research center, the Barcelonaβeta Brain Research Center (BBRC), with the support of the “la Caixa” Foundation, have detected that the glial fibrillar acid protein (GFAP) is a very accurate biomarker for diagnosing in blood the early stages of Alzheimer’s disease.